Physician profile
James Metkus
NPI 1376078758
$1,765.97
in general payments reported to CMS, 2019-2025
13 companies · $859 in 2025
The $859 reported for 2025 was more than what a typical Sleep Medicine (Otolaryngology) provider received nationally (typical 2025 total: $509).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $258 · 2023: $154 · 2024: $495 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013 · Travel and Lodging: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.29 |
| Travel and Lodging | $494.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,057.66 | 2024-2025 | Inspire |
| Genzyme Corporation | $256.68 | 2022-2025 | |
| Med-El Corporation | $103.90 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $90.16 | 2025 | Lumryz |
| Astrazeneca Pharmaceuticals Lp | $67.54 | 2025 | Fasenra, Airsupra |
| Integra Lifesciences Corporation | $42.35 | 2022 | |
| Stryker Corporation | $34.92 | 2023 | Na, Vsp System, Vsp Cranial, Smartlock |
| Regeneron Healthcare Solutions, INC. | $31.12 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $19.32 | 2025 | |
| Itamar Medical INC | $17.60 | 2025 | Watchpatone |
| Glaxosmithkline, LLC. | $15.88 | 2025 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.08 | 2025 | Ofev |
| Amgen INC. | $13.76 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Metkus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.